Next Article in Journal
Cytotoxic Sesquiterpene Lactones from Kauna lasiophthalma Griseb
Previous Article in Journal
Development and Validation of a Gas Chromatography Method for the Trace Level Determination of Allylamine in Sevelamer Hydrochloride and Sevelamer Carbonate Drug Substances
Article Menu

Article Versions

Export Article

Open AccessArticle
Sci. Pharm. 2014, 82(1), 129-146; doi:10.3797/scipharm.1306-18

Evaluation of Serum Levels of HER2, MMP-9, Nitric Oxide, and Total Antioxidant Capacity in Egyptian Breast Cancer Patients: Correlation with Clinico-Pathological Parameters

1
artment of Biochemistry, Faculty of Pharmacy, Mansoura University, Mansoura, 35516, Egypt
2
Oncology Center, Mansoura University, Mansoura, 35516, Egypt
*
Author to whom correspondence should be addressed.
Received: 30 June 2013 / Accepted: 22 September 2013 / Published: 22 September 2013
Download PDF [240 KB, uploaded 27 September 2016]

Abstract

Breast cancer is by far the most common cancer in women worldwide and the main cause of cancer-related mortality. Breast cancer accounts for 38% of all malignancies among Egyptian women. The aim of our study was to evaluate the serum levels of human epidermal growth factor receptor-2 (HER2), matrix metalloproteinase-9 (MMP-9), nitric oxide (NO), and total antioxidant capacity (TAC) in breast cancer patients and to correlate these markers with clinico-pathological parameters. Serum HER2, MMP-9, and carcinoma antigen 15-3 (CA 15-3) were assessed in 80 breast cancer patients and ten healthy subjects as a control group by the enzyme-linked immunosorbent assay (ELISA) technique while NO and TAC were assessed by a colorimetric method. Serum HER2 was ≥15 ng/mL in nine patients (11.3%). High HER2 ECD levels were significantly associated with tissue HER2 (P<0.0001), metastasis (P= 0.0024), and negativity of both estrogen (P=0.0075) and progesterone (P=0.0239) receptors. Serum MMP-9 (P=0.0013), NO (P<0.0001), and CA 15-3 (P<0.0001) were significantly increased while serum TAC was significantly (P=0.01) decreased in breast cancer patients as compared to the control group. Serum MMP-9 was increased significantly (P=0.028) in metastatic patients as compared to non-metastatic patients. We found a positive correlation between serum HER2 and CA 15-3 (r=36, p=0.005). In conclusion, serum HER2 reflects the tissue HER2 status of breast cancer, so the determination of serum HER2 is helpful in assessing HER2 status, but in addition, a high level may reflect metastatic disease. Also, serum MMP-9 can be useful for denoting the development of metastasis in breast cancer patients. Follow-up is needed to evaluate the value of serum HER2 and MMP-9 as prognostic markers.
Keywords: Human epidermal growth factor receptor-2 (HER2); Matrix metalloproteinase-9 (MMP-9); Nitric oxide (NO); Total antioxidant capacity (TAC); Carcinoma Antigen 15-3 (CA15-3); Breast cancer Human epidermal growth factor receptor-2 (HER2); Matrix metalloproteinase-9 (MMP-9); Nitric oxide (NO); Total antioxidant capacity (TAC); Carcinoma Antigen 15-3 (CA15-3); Breast cancer
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

RASHAD, Y.A.; ELKHODARY, T.R.; EL-GAYAR, A.M.; EISSA, L.A. Evaluation of Serum Levels of HER2, MMP-9, Nitric Oxide, and Total Antioxidant Capacity in Egyptian Breast Cancer Patients: Correlation with Clinico-Pathological Parameters. Sci. Pharm. 2014, 82, 129-146.

Show more citation formats Show less citations formats

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Sci. Pharm. EISSN 2218-0532 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top